CA-DLOCAL
26.8.2020 13:32:06 CEST | Business Wire | Press release
dLocal, an award-winning fintech company that specializes in cross-border payments for emerging markets, announced today that it is supporting Zara’s e-commerce operations in Uruguay and Paraguay through the use of its payments platform. This provides an enhanced online shopping experience for Zara’s customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200826005235/en/
Leveraging dLocal’s 360 payments platform, Zara (Inditex) will be able to accept local credit card payments with the option of monthly installments. The solution allows customers to pay with both international and locally issued credit cards from Mastercard, Visa and American Express, as well as other domestic cards such as OCA in Uruguay.
“We are proud to have Zara as a customer, to provide their international shoppers with an easier and faster online checkout experience by offering them multiple local payments methods,” said Michel Golffed, VP Growth, dLocal. “We have extensive experience in Uruguay and Paraguay, supporting hundreds of clients between the two countries, and we look forward to putting that expertise to work in helping Zara achieve success in the region.”
Meirav Adi, VP Sales, dLocal, said that localized payments have been proven beneficial for global retailers fostering e-commerce.
“Uruguay, for example, is an e-commerce-friendly market with a strong economy that’s projected to grow to $3.7 billion in 2021, with local debit cards making up about a third of the payments volume,” said Adi. “It’s the same story for many other high-potential markets around the world. Offering localized payment options isn’t a ‘nice to have,’ it’s a prerequisite for success.”
Local card acquiring is part of dLocal’s Payins solution that allows merchants to collect payments from their customers in emerging markets in their respective local currency. The major benefit for the merchant is the access to a variety of local payment methods as well as the possibility to receive funds in USD, EUR, or any other currency within the countries dLocal operates in. dLocal clients deploying the payins solution see an average increase of 20% in conversion rate.
With only a single integration to dLocal’s platform, the solution enables any merchant to immediately expand to all of the following 19 emerging markets:
- Latin America: Argentina, Brazil, Bolivia, Colombia, Chile, Ecuador, Mexico, Paraguay, Peru, Uruguay
- Africa: Egypt, Morocco, Nigeria, South Africa
- Asia: Bangladesh, China, India, Indonesia, Turkey.
For additional information on dLocal’s Payins solution read here .
About dLocal
dLocal (https://dlocal.com ) is the only 360 payments platform designed to handle mass online payments in Latin America and other emerging countries across APAC, Middle East and Africa. With dLocal’s single API platform, there is no need to manage separate payin and payout processors, set-up numerous local entities, integrate dozens of isolated acquirers and payment methods, worry about stranded funds overseas, nor undergo heavy operational burdens. By operating as the merchant’s local payments processor in each country, dLocal makes it simple for online companies to reach 2.3 billion digitally-savvy consumers in today’s fastest-growing markets.
Over 450 global e-commerce retailers, SaaS companies, online travel providers, and marketplaces rely on dLocal to accept over 300 locally-relevant payment methods, as well as issue millions of payments to their contractors, agents, and sellers in growth markets around the world. Some of dLocal's customers include Amazon, Avast, Banggood, Booking.com, Constant Contact, Didi, DropBox, Gearbest, GoDaddy, MailChimp, TripAdvisor, Uber, and Wikimedia. Visit dlocal.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200826005235/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 09:00:00 CEST | Press release
Partnership Will Enable Enterprises to Accelerate AI Adoption While Ensuring Digital Sovereignty ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to oper
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
